Table 2.
Ongoing clinical trials of T-VEC in skin cancers.
| Reference | Study Drugs/Mechanisms of Action | Stage (n) |
Disease | Treatment | Key Outcomes | |
|---|---|---|---|---|---|---|
| 1 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) |
TVEC/OVT Pembrolizumab/PD-1 inhibitor |
Phase II (n = 47) |
Advanced Melanoma Refractory Melanoma |
Pembrolizumab and TVEC combination | Objective response rate, median progression-free survival, median overall survival |
| 2 | T-VEC in Non-melanoma Skin Cancer (NCT03458117) |
TVEC/OVT | Phase I (n = 26) |
Non-melanoma Skin Cancer Basal Cell Carcinoma Squamous Cell Carcinoma Cutaneous Lymphoma Merkel Cell Carcinoma |
TVEC | Local immune response, systemic immune response |
| 3 | Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) |
TVEC/OVT Nivolumab/PD-1 inhibitor |
Phase II (n = 68) |
Refractory T cell Lymphoma Refractory NK cell lymphoma Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma Other Rare Skin Tumors |
TVEC followed by nivolumab and TVEC combination | Response rate, best overall response rate, progression-free survival, overall survival |
| 4 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer (NCT03714828) |
TVEC/OVT | Phase II (n = 11) |
Cutaneous Squamous Cell Cancer | TVEC | Overall response rate (ultrasound, targeted lesions, non-injected lesions) |
| 5 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (NCT04163952) |
TVEC/OVT Panitumumab/Anti-EGFT monoclonal antibodies |
Phase I (n = 5) |
Advanced Squamous Cell Cancer | Panitumumab and TVEC combination | Response rate, best overall response rate, progression-free survival, overall survival |